Machine Learning-Based Screening of Risk Factors and Prediction of Deep Vein Thrombosis and Pulmonary Embolism After Hip Arthroplasty

Clin Appl Thromb Hemost. 2023 Jan-Dec:29:10760296231186145. doi: 10.1177/10760296231186145.

Abstract

Prophylactic anticoagulation is a standard strategy for patients undergoing total hip arthroplasty (THA) to prevent deep venous thromboembolism (DVT) and pulmonary embolism (PE). Nevertheless, some patients still experience these complications during their hospital stay. Current risk assessment methods like the Caprini and Geneva scores are not specifically designed for THA and may not accurately predict DVT or PE postoperatively. This study used machine learning techniques to establish models for early diagnosis of DVT and PE in patients undergoing THA. Data were collected from 1481 patients who received perioperative prophylactic anticoagulation. Model establishment and parameter tuning were performed using a training set and evaluated using a test set. Among the models, extreme gradient boosting (XGBoost) performed the best, with an area under the receiver operating characteristic curve (AUC) of 0.982, sensitivity of 0.913, and specificity of 0.998. The main features used in the XGBoost model were direct and indirect bilirubin, partial activation prothrombin time, prealbumin, creatinine, D-dimer, and C-reactive protein. Shapley Additive Explanations analysis was conducted to further analyze these features. This study presents a model for early diagnosis DVT or PE after THA and demonstrates bilirubin could be a potential predictor in the assessment of DVT or PE. Compared to traditional risk assessment, XGBoost has a high sensitivity and specificity to predict DVT and PE in the clinical setting. Furthermore, the results of this study were converted into a web calculator that can be used in clinical practice.

Keywords: deep vein thrombosis; machine learning; perioperation; pulmonary embolism; risk assessment.

MeSH terms

  • Anticoagulants
  • Arthroplasty, Replacement, Hip* / adverse effects
  • Humans
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / etiology
  • Pulmonary Embolism* / prevention & control
  • Risk Factors
  • Venous Thrombosis* / diagnosis
  • Venous Thrombosis* / etiology
  • Venous Thrombosis* / prevention & control

Substances

  • Anticoagulants